SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's GOOG is trending due to growing investor confidence in its AI capabilities, particularly with the recent unveiling of Gemini 3, which is seen as a strong competitor to existing AI models. Community discussion revolves around GOOG potentially overtaking NVDA in market capitalization, with some analysts suggesting Google's long-term growth potential is being re-evaluated, leading to a shift in market sentiment.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet (GOOGL) is trending as investors discuss its potential to lead in AI, fueled by positive reviews of its Gemini 3 model and a recent investment by Berkshire Hathaway. Community members are weighing in on whether the stock's rapid growth is sustainable, while highlighting its competitive position against companies like Nvidia and OpenAI. Some traders are noting technical indicators that may signal a pullback is coming.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is trending upwards as the community discusses potential M&A activity and positive momentum within the biotech sector. Positive clinical data and new FDA pathways are also sparking interest, while some analysts point to attractive valuations compared to peers. Concerns about data integrity for specific companies are also circulating.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending amid discussions about its role in AI, particularly following reports that Google's Gemini 3 model utilizes Broadcom's TPUs, sparking debates about competition with Nvidia. Bullish sentiment and high price targets are fueled by expectations of strong earnings, while some traders are closely monitoring technical indicators and potential pullbacks. The community is also weighing the stock's valuation and its long-term potential within the growing AI landscape.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPM is trending amid discussions around potential investigations related to Jeffrey Epstein, its relationship with crypto companies like $MSTR, and overall sentiment regarding the financial sector. Some traders are considering shorting the stock, while others point to positive technical indicators and potential upside. The community is also discussing JPM's role in the broader market and its impact on individual stocks.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending amid discussions about immigration policies and detention facilities, with community members sharing news articles and discussing potential impacts on the company. Some traders are highlighting options strategies, while others are debating the company's financial outlook and potential for government contracts in light of political developments. The stock's valuation and buyback program are also key talking points.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as community members rally around its meme-driven narrative and organic growth on the SOL network. The community, known for its active presence and lighthearted approach, emphasizes that the "infection" is spreading, with community members using the hashtag #PMV. Participants suggest that the coin's current levels present an attractive entry point.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending due to a mix of factors including upcoming earnings and community speculation around AI initiatives. Recent news of their Qwen AI app reaching 10 million downloads has sparked bullish sentiment, countered by reports alleging ties to the Chinese military, creating volatility. Discussions revolve around whether the company can maintain growth amid competition and broader geopolitical concerns.

The KARRAT protocol is a decentralized gaming infrastructure layer, supported by $KARRAT and empowered by a truly decentralized community with a shared vision embracing gaming, entertainment and AI products catering for the new era.  To accelerate the evolution of gaming, entertainment, and AI-driven experiences with blockchain technology and a truly empowered community.  The KARRAT protocol pioneers a decentralized framework in gaming and entertainment, combining blockchain with community-driven collaboration. $KARRAT can animate ecosystems of games and products and the protocol makes tools available to support these industries and the adoption of KARRAT technology provides a unique, personalized gaming experience.

KARRAT

Karrat is trending as community members anticipate a potential run, with some eyeing a 10x increase. Talk centers on accumulating the token, especially below a certain price point, with expectations that Karrat could trade independently of larger cryptocurrencies like Bitcoin and Ethereum. Some traders point to the gaming sector and partnerships as potential catalysts for future growth.

Mason Capital Fund Trust - Fundamentals First ETF

KNOW Labs is trending, with discussions focusing on the company's plan to apply for listing on the NYSE American under the symbol "KNW." The community is also comparing KNOW's technology to competitors in the medical device space, specifically highlighting its non-invasive glucose monitoring device. Some users are speculating about a potential gamma squeeze and NASDAQ listing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Xilio Therapeutics ended nearly 8% higher on Tuesday after the company reported positive early trial results for its cancer drug XTX301, began dosing patients in Phase 2, and secured a $17.5 million milestone payment from Gilead Sciences.Xilio said Phase 1 data for XTX301, a tumor-activated IL-12 therapy, showed anti-tumor activity in patients with advanced solid tumors, including two partial responses, while most side effects were mild or moderate.&nbsp;The treatment also sustained interferon gamma signaling across cycles, supporting the company’s approach of reprogramming “cold” tumors into inflamed “hot” ones.Based on the findings, Xilio selected a recommended Phase 2 dose and schedule and has begun treating patients in the Phase 2 portion of its ongoing Phase 1/2 trial in the U.S, which will enroll about 40 participants.&nbsp;Enrollment in Phase 1A has been completed, and Phase 1B expansion is still underway.The milestone payment from Gilead, tied to the start of Phase 2, extends Xilio’s cash runway into the first quarter of 2027. As of June 30, the company held $121.6 million in cash and equivalents and expects to receive the Gilead payment in the fourth quarter of 2025.Under their March 2024 global license agreement, Gilead may take over development and commercialization of XTX301 after reviewing clinical data, with an option fee of $75 million.&nbsp;Xilio could receive up to $500 million in additional development, regulatory and sales milestones, plus tiered royalties ranging from high single digits to mid-teens on global net sales.On Stocktwits, retail sentiment for Xilio was ‘bullish’ amid a 2,333% surge in 24-hour message volume.One user said that the stock had “solid news” but needed more trading volume to push through the $0.80 level.<stembedurl>https://stocktwits.com/MrTicker/message/627979369</stembedurl>Another user predicted the shares would climb quickly, noting it was “super hard to get shares.”&nbsp;They highlighted that Xilio held about $140 million in cash against a roughly $38 million market cap, arguing the market had assigned little to no value to its partnerships, assets, or even its cash balance, and suggesting a reprice was likely.<stembedurl>https://stocktwits.com/SteadyTrade55/message/627979366</stembedurl><a href="https://stocktwits.com/symbol/XLO">Xilio’s stock</a> has declined 21.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Xilio’s stock has declined 21.5% so far in 2025. (Photo credit: Getty Images)

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.

Equity

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

TD Cowen Remains a Buy on Xilio Therapeutics (XLO)

TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO Research Report) yesterday. The company's shares closed yesterday...

Xilio Therapeutics reports Q4 results

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...

12 titoli sanitari in movimento, sessione regolare del 01/04/2024

Titoli in rialzo
Le azioni di Sunshine Biopharma (NASDAQ:SBFM) hanno fatto segnare +84,29% a 0,11 dollari durante la sessione regolare di luned .
Le azioni di Xilio Therapeutics (NASDAQ:XLO) sono...

12 acciones de salud en movimiento en la sesi n intrad a del 01/04/2024

Acciones al alza
Sunshine Biopharma (NASDAQ:SBFM) se anotaron un alza del 93,22% para establecerse en los 0,12 d lares durante la sesi n del regular del lunes.
Xilio Therapeutics (NASDAQ:XLO) ganaron...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 29/03/2024

Gagnants
Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market.
Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Xilio Therapeutics Inc

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

XLO
Xilio Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XLO News

XLOXilio Therapeutics Inc